Until recently, the CMG has provided genetic testing services for HIV drug resistance using NGS, preimplantation genetic diagnosis for aneuploidies, BRCA1/2 testing using NGS technology for breast and ovarian cancer risk prediction, noninvasive prenatal testing (NIPT), and hereditary cardiomyopathy panel testing using NGS technology [9]. This evidence concerns the gene BRCA1 and ovarian cancer.